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ABSTRACT
Antimicrobial de-escalation (ADE) is a compo-
nent of antimicrobial stewardship (AMS) aimed
to reduce exposure to broad-spectrum antimi-
crobials. In the intensive care unit, ADE is a
strong recommendation that is moderately
applied in clinical practice. Following a sys-
tematic review of the literature, we assessed the
studies identified on the topic which included
one randomized controlled trial and 20 obser-
vational studies. The literature shows a low level
of evidence, although observational studies
suggested that this procedure is safe. The effects
of ADE on the level of resistance of ecological
systems and especially on the microbiota are
unclear. The reviewers recommend de-escalat-
ing antimicrobial treatment in patients requir-
ing long-term antibiotic therapy and
considering de-escalation in short-term
treatments.
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Key Summary Points
Antibiotic de-escalation (ADE) was first
implemented to reduce exposition to
broad-spectrum antibiotics in the ICU. It
is now part of the antimicrobial
stewardship and is recommended in
international guidelines.
This systematic review aimed to evaluate
the level of evidence regarding the safety
of ADE (mortality, superinfections and
duration of antimicrobial therapy) and
the emergence of antibiotic resistance.
Data related to safety showed with a low
evidence level to support the safety of
ADE. No conclusion can be drawn on the
level of resistance after de-escalation.
The reviewers recommend de-escalating
antimicrobial treatment in patients
requiring long-term antibiotic therapy
and discussing the need for de-escalation
for patients requiring short-term
treatments.
INTRODUCTION
Antimicrobial de-escalation (ADE) is a compo-
nent of antimicrobial stewardship (AMS) aimed
to reduce exposure to broad-spectrum antimi-
crobials. Broad-spectrum antimicrobials are
widely used in intensive care units (ICUs), often
empirically in the treatment of patients with
life-threatening infections [1].
The Surviving Sepsis Campaign guidelines
[2] recommend early administration of broad-
spectrum antimicrobials to patients with sepsis.
This may be achieved with administration of a
pivotal antibiotic, most often a beta-lactam,
accompanied by an additional antimicrobial
intended to extend the spectrum, create a syn-
ergy between some antibiotics and reduce the
emergence of antimicrobial resistance. This
recommendation was strong and clear despite
being based solely on observational studies
reporting associations between delays in
antimicrobial administration and mortality
rates. However, it was not universally supported
by the entire scientific community, notably the
Infectious Diseases Society of America [3]. The
Surviving Sepsis Campaign guidelines also rec-
ommended daily assessment for possible ADE in
these patients. Lacking evidence, this recom-
mendation was classified as a best practice
statement. The current paper reviews the defi-
nition, the principles and the ecological conse-
quences of ADE.
METHOD
For the purpose of this review we conducted a
systematic search of the Pubmed database from
January 1, 2005 until January 15, 2020 for
studies on ICU patients (P) describing de-esca-
lation of antibiotic therapy (I) versus continua-
tion without de-escalation (C) in relation to
either patient outcomes or antimicrobial resis-
tance profiles (O). The study was registered in
PROSPERO (CRD42020169433). Details regard-
ing the search methodology, study inclusion
criteria and method used to assess the quality of
the included studies are provided in the sup-
plementary material.
We identified one randomized controlled
trial (RCT) [4] and 20 observational studies
describing ADE in ICU patients [5–24]. We
excluded studies evaluating antifungal de-esca-
lation alone as well as case reports, case series
and reviews. We also excluded papers not in the
English language and/or those conducted on
animal models or the paediatric population.
The 20 observational papers were assessed for
quality using the Newcastle Outcome Score
(Table 3). This article is based on previously
conducted studies and does not contain any
studies with human participants or animals
performed by any of the authors.
PRINCIPLES
The goals of ADE and the actions that may be
considered ADE are listed in Table 1. The main
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criterion used to determine whether successive
use of different antibiotics can be considered de-
escalation is the ranking of the spectrum of
antimicrobial coverage of these antibiotics. Two
reports have attempted to rank antibiotics
directed against Gram-negative bacteria,
resulting in divergent findings (Table 2).
Madaras-Kelly et al. scored antibiotic regimens
on the basis of the susceptibilities of different
microorganisms of clinical interest to each reg-
imen [25]. Using this computed antibiotic regi-
men score they then ranked a total of 27
antibiotics ranging from a minimum score of 4
(metronidazole) to a maximum score of 49.75
(tigecycline). The authors then asked a group of
experts to determine whether specific changes
in antibiotic regimen are ADEs or not. The
responses of the experts did not correlate well
with ADEs as defined by the calculated scores,
underscoring the complexity of bench to bed-
side translation of ADE. Weiss et al. used a
Delphi process to rank six b-lactam antibiotics
according to their spectrum and their ecological
impact on the microbiota [26]. The Delphi
process consisted of obtaining consensus based
on the results of multiple rounds of question-
naires sent to a panel of experts. Ranking of
ureido/carboxy-penicillins, and third- and
fourth-generation cephalosporins needed addi-
tional voting rounds as there was less agreement
between the voters on these drugs than there
was on other molecules. This lack of consensus
is probably mostly attributable to a lack of data
regarding the effect of these molecules on the
microbiota [26], but it can also be related to the
fact that the effects of antibiotics depend on the
ecosystem (ICU, hospital, country) where they
are used. Furthermore, as shown in Table 2, the
Table 1 Goals and actions considered ADE (antimicro-
bial de-escalation)
The goals of therapy are theoretically [3]
Broadening the spectrum of antimicrobial therapy by
administering different agents acting on different
families of pathogens. This increases the likelihood
that any responsible pathogen will be susceptible to at
least one of the administered agents
Improving the lethality of the treatment on the basis
of a possible synergistic effect
Preventing or delaying the emergence of resistance
A large number of actions can be considered ADE,
making it challenging to reach a consensus
Narrowing the spectrum of the pivotal antimicrobial
Early discontinuation of one or several antimicrobials
of a combination therapy
Early discontinuation of antimicrobial treatment. This
has been excluded from the definition of ADE in the
last consensus statement [1]
Table 2 Differences in antibiotic ranking according to Weiss et al. and Madaras-Kelly et al.
Weiss et al. Agent Madaras-Kelly et al.
Rank Similar response (%)a Spectrum score Rank
1 100 Amoxicillin 13.5 1
2 88 Amoxicillin/clavulanate 29.5 3
3 81 3rd-generation cephalosporin 25.5 2
4 71 Piperacillin/tazobactam 42.25 7
4th-generation cephalosporin 33.25 5
5 81 Ertapenem 30.25 4
6 85 Imipenem 41.5 6
a Indicates the proportion of experts that agreed with the molecules included in each rank of the classification
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two scores are also significantly different. At this
time, most experts recommend that each insti-
tution creates its own ranking based on local
epidemiology [1] and antimicrobial availability.
DEFINITION
In order to best define ADE, international
experts (n = 16) were requested to define what
constitutes ADE in their opinion. The experts
were also asked their opinion as to how ADE
should be implemented in clinical practice [1].
Expert selection was based on prior publications
in the field of antimicrobial stewardship, expe-
rience with systematic reviews and group writ-
ing. Thirteen issues related to the definition of
ADE were put forward by the participants.
Lacking data, a Delphi method was used to
reach expert consensus regarding the final ver-
sion of the definition. Votes were conducted
anonymously, in a blinded fashion, and occur-
red after collective discussion of each proposal.
The number of allowable voting rounds was pre-
set to a maximum of three and consensus was
predefined as 70% agreement. The final defini-
tion of ADE decided upon comprised the
following:
1. Replacing administration of broad-spec-
trum antimicrobials with agents having a
narrower spectrum of antimicrobial cover-
age or local ecological impact.
2. Stopping administration of components of
an antimicrobial combination. Two differ-
ent situations were included in this defini-
tion.
2a. Stopping administration of an antimi-
crobial agent administered as a com-
ponent of combination therapy in
order to provide double coverage for
certain pathogens.
2b. Stopping administration of an antimi-
crobial agent given empirically, fol-
lowing verification that the covered
pathogens have not been isolated in
clinical cultures.
3. Early discontinuation of all antimicrobial
therapy once infection has been ruled out is
not considered de-escalation [1].
PATIENT PERSPECTIVE: SAFETY
OF ANTIMICROBIAL DE-
ESCALATION
Data on patient outcomes and the safety of ADE
are reported in Table 3.
Association of ADE with Mortality
The non-blinded RCT published by Leone et al.
was a multicentre non-inferiority trial assessing
ADE versus continuation of empirical treatment
in 120 patients. The study showed that for the
primary endpoint—ICU length of stay—ADE
did not reach the margin of non-inferiority
compared with continuation (15.2 ± 15.0 days
for ADE versus 11.8 ± 12.6 days for continua-
tion, p = 0.71, non-inferiority margin 2 days).
No difference was also observed in 28-day
mortality (31% with ADE group versus 23%
with treatment continuation, p = 0.55) [4].
Among the 20 observational studies, differ-
ences in mortality between ADE and non-ADE
were found to be not statistically significant in
14 studies and significantly decreased in the de-
escalation arm in six studies
[6, 7, 12, 13, 20, 23]. None showed an increased
mortality associated with ADE. Data synthesis
of the observational studies suggests that ADE is
associated with lower mortality with a relative
risk at 0.71 and a 95% confidence interval from
0.63 to 0.80, but substantial heterogeneity was
identified between studies with regards to this
outcome (I2 = 49%) (Fig. 1).
Definition of ADE was highly variable in
observational studies; therefore, a sensitivity
analysis was further performed to assess only
studies not including early antibiotic cessation
in the definition of ADE. The sensitivity analysis
found a relative risk at 0.67 with a 95% confi-
dence interval from 0.59 to 0.76 (details and
forest plot in supplementary material). How-
ever, the data were not adjusted in any of the
studies.
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Association of ADE with Superinfections
and Duration of Antimicrobial Therapy
The RCT showed that ADE was associated with a
higher number of superinfections and a subse-
quent increase in duration of antimicrobial
therapy compared to continuation (27% in ADE
versus 11% in non-ADE, p = 0.03). However, the
trial was not powered for this outcome.
Six observational studies, which did not
include early cessation of antimicrobials in the
definition of ADE, reported on these outcomes
(n trials = 6, n patients = 1444). Three showed
similar durations of antibiotic treatment
[5, 10, 13], two showed an increase in duration
with ADE [11, 24] and one showed a decrease in
duration with ADE [15].
Two reasons were put forward for the
increased duration of treatment observed in two
of the studies. These included superinfections
and mistaken perceptions that prolonged
treatment are reasonable with narrow-spectrum
but not broad-spectrum antibiotics. This
finding prompted a recommendation by the
authors of this paper that clinicians should
consider limiting the duration of antimicrobial
therapy regardless of the spectrum of antibiotic
coverage. Shortening the duration of antibiotic
therapy is one of the strategies proven to
decrease antibiotic resistance [27].
A topic not addressed in any of the papers
was the risk of inadequate dosing during ADE.
Carlier et al. showed that the probability of
reaching pharmacokinetic/pharmacodynamic
(PK/PD) targets during de-escalating from a
broad-spectrum antimicrobial to a narrow-
spectrum antimicrobial is low when using usual
antimicrobial doses [28]. Recommendations for
narrow-spectrum antibiotics dosage are identi-
cal for ICU and non-ICU patients. Yet, ICU
patients commonly have altered distribution
volumes and renal function. Therefore, PK/PD
adjustments are probably needed during ADE,
as recommended for all antimicrobial treatment
[29].
In brief, the only existing RCT included a
small number of patients and it was not
Fig. 1 Difference in patient mortality rates between antimicrobial de-escalation (ADE) and non-ADE
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powered to meet some of the important end-
points. The observational studies have a signif-
icant risk of inclusion bias; patients treated with
ADE were mostly less severe than those con-
tinuing antibiotic treatment [21] (Table 3). Even
with the use of statistical adjustment such as
logistic or linear regression analysis
[5, 8, 10, 22], and propensity score matching
[7, 15], the risk of bias remains [30]. In obser-
vational studies, several risk factors for not
implementing ADE were found including high
patient’s severity [7, 8, 12, 15, 20, 23], identifi-
cation of a multidrug-resistant (MDR) pathogen
in the cultures [5, 11, 13, 18, 19, 22], presence of
multiple pathogens in the cultures [7, 8, 23], a
non-microbiologically documented infection
[11, 14] or infections with a high risk of undi-
agnosed pathogens such as intra-abdominal
infections [7, 12, 18]. Finally, ADE may reflect
better management by the physician in charge.
To date, the lack of high-quality data ham-
pers provision of strong recommendations. The
authors therefore chose to adhere to the
recently published position statement on ADE
which suggested that ADE may be safe in most
patients if the practice is included in a global
antimicrobial stewardship program [1]. At this
time three RCTs are ongoing on this topic.
These studies are recruiting patients with bac-
teraemia, malignancy and sepsis or septic shock
and infections in the ICU (overall n = 1460)
[31–33]. It is hoped that their additional data
will enable one to draw conclusions on this
issue.
EPIDEMIOLOGICAL PERSPECTIVE:
DE-ESCALATION AND EMERGENCE
OF ANTIBIOTIC RESISTANCE
ADE was introduced to reduce the emergence of
antimicrobial resistance (AMR) [2]. The evi-
dence regarding the relation between de-esca-
lation and emergence of AMR can be divided
into direct and indirect evidence. The former
relates to studies showing an association
between ADE and resistance in human subjects.
The latter relates to recent evidence on the
effect of antimicrobials on the microbiome [34].
Direct Evidence
At this time the evidence does not show the
presence of an association between ADE and
decreased emergence of MDR. De Bus et al. [11]
retrospectively assessed observational data,
seeking emergence of antimicrobial resistance
after ADE in infected ICU patients treated with
anti-pseudomonal b-lactams. They found no
significant differences in the emergence of MDR
bacteria at day 14 (23.5% in the de-escalation
group versus 18.6% in the continuation group,
p = 0.2). Leone et al. assessed emergence of
MDR bacteria on day 8 as a secondary endpoint
in their RCT and showed no difference between
fixed treatment and de-escalation [4].
A cohort study of adults with severe sepsis or
septic shock (n = 7118) showed that each addi-
tional day of exposure to cefepime, meropenem
and piperacillin-tazobactam was associated with
increased development of resistance [35]. How-
ever, three other retrospective observational
studies, which assessed antimicrobial resistance
as secondary endpoints, identified no statisti-
cally significant association between ADE and
resistance emergence [10, 15, 22]. The first
assessed ADE in septic ICU patients (n = 229).
ADE was performed in 51% of patients. The
incidence of emergence of MDR bacteria at the
time of last ICU screening was 15.3% with ADE
versus 10.7% with continued treatment
(p = 0.1). In this study, ADE led to more MDR
infections, but the difference remains not sta-
tistically significant [22]. The second studied
ICU patients with ventilator-associated pneu-
monia (n = 182). ADE was performed in 38% of
cases. The incidence of emergence of MDR
bacteria by day 21 was 14.3% with ADE versus
21.3% with continued treatment (p = 0.3) [10].
The third study compared patients matched
with propensity scoring (n = 84) and showed
that the incidence of emergence of antimicro-
bial resistance during ICU admission was 31%
with ADE versus 40.5% with continued treat-
ment (p = 0.3) [15].
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Indirect Evidence
The intestinal microbiota is an independent
organ wherein MDR bacteria may emerge [34].
The microbiota is a complex ecosystem, con-
taining between 1012 and 1014 bacteria per gram
of stool. The extent and complexity of the
microbiota are such that the metaphor of ‘‘black
matter’’ has been used to describe how little we
know about it [36]. Several techniques are cur-
rently being developed to assess the microbiota.
Among these, metagenomics, also called Next
Generation Sequencing (NGS), is increasingly
being used in clinical settings [37]. NGS has
several advantages over traditional methods.
One is that it obviates the need for bacterial
culture, which allows detection of fastidious
bacteria. Another advantage of NGS is that it
assesses the full antimicrobial resistome (i.e. the
presence and interaction of genes encoding
antimicrobial resistance in a given microbiome)
[38]. The combination of these advantages is of
particular interest; the microbiota of the human
gut is a hub for horizontal exchange of genetic
material between bacteria [39]. Therefore
transfer of genetic material conferring antimi-
crobial resistance to non-pathogenic bacteria
may be as harmful as its presence in pathogenic
bacteria [40]. NGS detects the presence of
antimicrobial resistance genes (thereby map-
ping their potential deleterious effects), regard-
less of the bacteria hosting those genes.
As mentioned above, ADE was first imple-
mented on the basis of the hypothesis that
reducing the duration of exposure to broad-
spectrum antimicrobials would lead to less
emergence of antimicrobial resistance. Woer-
ther et al. reported that the administration of
imipenem may have little effect on the diversity
of the microbiota and its colonization resis-
tance, despite the fact that imipenem is a broad-
spectrum antibiotic [41]. Other antimicrobials,
such as piperacillin/tazobactam or ceftriaxone,
have been implicated in greater detrimental
effects on the gut microbiota. The causes put
forward for this difference include antimicrobial
features such as the degree of biliary excretion,
the spectrum of anti-anaerobic activity and/or
the extent of accumulation in the gastroin-
testinal tract. All of these could potentially lead
to disruption of the normal bacterial balance
with resultant disturbances in colonization
resistance, diversity and balance between phyla
[34, 41]. Disruption of colonization resistance is
of concern because in the vaccum created, col-
onization is more likely to occur with MDR
bacteria (Fig. 2). Nevertheless, ceftriaxone and
piperacillin/tazobactam are often considered for
de-escalation from carbapenems [34].
Furthermore, even if ADE reduces the dura-
tion of exposure to broad-spectrum antibiotics,
detrimental effects on microbiota can still occur
in a short period of time. Armand-Lefe`vre et al.
showed that ICU patients exposed to 1–3 days
of imipenem had an increased risk of emergence
of imipenem-resistant Gram-negative bacilli
(odds ratio 5.9, 95% CI 1.5–25.7) [42]. There-
fore, especially for short duration treatments, a
brief exposure to broad-spectrum antimicrobials
followed by a reduction in the antimicrobial
spectrum may result in a cumulative effect of
different lines of antimicrobials rather than a
reduction in the impact on resistances.
Studies have assessed the resistome in ICU
patients exposed to antibiotics [43, 44] and in
animals exposed to antibiotics [45]. Buelow
et al. [43] compared the resistomes of ICU
patients and healthy volunteers exposed to
antibiotics in the setting of selective digestive
tract decontamination (SDD). Ten patients
received antimicrobials for SDD: cefotaxime,
polymyxin E (colistin), tobramycin and
amphotericin B. The resistome of ICU-SDD
treated patients differed from that of healthy
volunteers and the microbiota of ICU patients
was less diverse than that of healthy volunteers.
Cessation of SDD and ICU discharge were
associated with recolonization by MDR bacteria,
confirming the hypothesis that a less diverse
microbiota is less resistant to colonization in
ICU patients. The integrity of the microbiota is
crucial in the battle against bacterial coloniza-
tion; antibiotic-associated destruction of one or
more phyla could provide the opening for per-
sistent installation of MDR pathogens.
Willmann et al. [44] also assessed the resis-
tome of ICU patients in relation to the type of
administered antibiotics. The resistomes of
hematological patients receiving prophylactic
treatment with either cotrimoxazole or
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ciprofloxacin were compared. The introduction
of antibiotics was associated with a substantial
increase in antimicrobial resistance gene con-
tent. Those treated with cotrimoxazole also
showed an increase of antimicrobial resistance
genes carried by plasmids (plasmidome). These
findings highlight the need for prudent use of
antimicrobials and better antibiotic selection
according to their impacts on the emergence of
bacterial resistance. These studies provide indi-
rect evidence that shuffling antibiotics may
have a deleterious cumulative effect on the
microbiome as each antibiotic probably has an
individual effect on the resistome.
In brief, indirect evidence suggests that
reducing exposure to broad-spectrum antimi-
crobials should be promoted. However, the
scarcity of microbiological data does not make
it possible to answer the question whether ADE
has an effect on the development of antimi-
crobial resistance. Recent guidelines highlight
this lack of evidence [1].
OUR RECOMMENDATIONS
FOR CLINICAL PRACTICE: EXPERT
OPINION
On the basis of the above evidence, we can draw
conclusions for the clinical vignette. For infec-
tions for which treatment is expected to be
short (5–7 days), no benefit has been shown for
ADE. Examples include pneumonia, uncompli-
cated peritonitis and urinary tract infections. If
antibiotic susceptibility is known by day 3,
whether the antibiotics should be changed is
matter for discussion. It is acceptable in such
cases to continue the same antibiotic rather
than exposing the patient to an additional
antibiotic with a whole different spectrum of
coverage and a different effect on the micro-
biota (expert opinion). If prolonged antibiotic
treatment is expected (i.e. more than 5–7 days),
ADE should be performed as early as possible.
CHALLENGES AND FUTURE
PERSPECTIVES
As mentioned above, further research is needed
to provide strong evidence in the field of ADE.
The three ongoing studies are expected to
Fig. 2 Antimicrobial induced alterations of the gut microbiota
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provide information with regards to the safety
of ADE in terms of mortality and superinfec-
tions. However, studies aimed at assessing the
impact of ADE on the emergence of AMR are
still required. These should be RCTs that mea-
sure the effect of ADE on the microbiota of the
individual patients undergoing treatment and
on the ICU ecosystem as a whole.
CONCLUSION
In this project experts in antimicrobial stew-
ardship reviewed the existing literature and
concluded that major questions remain regard-
ing the clinical practice of ADE. We identified
only one RCT on the topic and data are still
lacking regarding adjusted patient outcomes
and the effects of ADE on the emergence of
antimicrobial resistance. Further research is
needed to answer these questions.
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